Ameriprise’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.69M | Buy |
261,310
+43,799
| +20% | +$848K | ﹤0.01% | 2350 |
|
|
2025
Q4 | $4.68M | Buy |
217,511
+224
| +0.1% | +$4.72K | ﹤0.01% | 2473 |
|
|
2025
Q3 | $4.19M | Sell |
217,287
-243,713
| -53% | -$4.34M | ﹤0.01% | 2559 |
|
|
2025
Q2 | $7.88M | Buy |
461,000
+124,211
| +37% | +$5.3M | ﹤0.01% | 2001 |
|
|
2025
Q1 | $21.5M | Buy |
336,789
+25,776
| +8% | +$2.71M | 0.01% | 1266 |
|
|
2024
Q4 | $37.8M | Sell |
311,013
-6,288
| -2% | -$771K | 0.01% | 987 |
|
|
2024
Q3 | $39.6M | Buy |
317,301
+8,888
| +3% | +$1.23M | 0.01% | 954 |
|
|
2024
Q2 | $48.7M | Buy |
308,413
+77,591
| +34% | +$9.97M | 0.01% | 810 |
|
|
2024
Q1 | $29.9M | Sell |
230,822
-194
| -0.1% | -$23.8K | 0.01% | 1057 |
|
|
2023
Q4 | $22.3M | Sell |
231,016
-522,189
| -69% | -$50.1M | 0.01% | 1208 |
|
|
2023
Q3 | $91.3M | Sell |
753,205
-12,988
| -2% | -$1.47M | 0.03% | 531 |
|
|
2023
Q2 | $87.7M | Buy |
766,193
+16,947
| +2% | +$2.19M | 0.03% | 552 |
|
|
2023
Q1 | $103M | Buy |
749,246
+150,748
| +25% | +$19.6M | 0.03% | 481 |
|
|
2022
Q4 | $77.6M | Sell |
598,498
-176,835
| -23% | -$20.5M | 0.03% | 559 |
|
|
2022
Q3 | $85.7M | Buy |
775,333
+74,573
| +11% | +$7.52M | 0.03% | 502 |
|
|
2022
Q2 | $52.2M | Sell |
700,760
-282,114
| -29% | -$20.8M | 0.02% | 703 |
|
|
2022
Q1 | $76.8M | Sell |
982,874
-114,169
| -10% | -$8.74M | 0.02% | 630 |
|
|
2021
Q4 | $98.8M | Buy |
1,097,043
+153,594
| +16% | +$13.1M | 0.03% | 578 |
|
|
2021
Q3 | $87.6M | Sell |
943,449
-172,341
| -15% | -$13.3M | 0.03% | 559 |
|
|
2021
Q2 | $86.7M | Sell |
1,115,790
-24,503
| -2% | -$1.86M | 0.03% | 575 |
|
|
2021
Q1 | $85M | Sell |
1,140,293
-457,038
| -29% | -$42.2M | 0.03% | 567 |
|
|
2020
Q4 | $272M | Buy |
1,597,331
+50,189
| +3% | +$7.44M | 0.1% | 225 |
|
|
2020
Q3 | $217M | Buy |
1,547,142
+35,395
| +2% | +$5.38M | 0.09% | 239 |
|
|
2020
Q2 | $242M | Sell |
1,511,747
-95,023
| -6% | -$12.9M | 0.1% | 209 |
|
|
2020
Q1 | $157M | Buy |
1,606,770
+205,465
| +15% | +$23.5M | 0.08% | 241 |
|
|
2019
Q4 | $181M | Buy |
1,401,305
+361,989
| +35% | +$36.5M | 0.08% | 266 |
|
|
2019
Q3 | $78.3M | Sell |
1,039,316
-238,941
| -19% | -$28.2M | 0.04% | 492 |
|
|
2019
Q2 | $194M | Buy |
1,278,257
+128,057
| +11% | +$15.6M | 0.09% | 241 |
|
|
2019
Q1 | $137M | Buy |
1,150,200
+873,817
| +316% | +$112M | 0.06% | 314 |
|
|
2018
Q4 | $30.2M | Sell |
276,383
-68,847
| -20% | -$8.61M | 0.02% | 843 |
|
|
2018
Q3 | $55.8M | Buy |
345,230
+23,931
| +7% | +$3.27M | 0.02% | 699 |
|
|
2018
Q2 | $42.2M | Sell |
321,299
-299,119
| -48% | -$28.2M | 0.02% | 744 |
|
|
2018
Q1 | $46M | Buy |
620,418
+516,223
| +495% | +$34.4M | 0.02% | 704 |
|
|
2017
Q4 | $5.8M | Sell |
104,195
-4,885
| -4% | -$259K | ﹤0.01% | 2021 |
|
|
2017
Q3 | $4.95M | Buy |
109,080
+66,591
| +157% | +$2.66M | ﹤0.01% | 2095 |
|
|
2017
Q2 | $1.43M | Buy |
42,489
+8,581
| +25% | +$279K | ﹤0.01% | 2768 |
|
|
2017
Q1 | $544K | Buy |
33,908
+18,297
| +117% | +$566K | ﹤0.01% | 3146 |
|
|
2016
Q4 | $428K | Sell |
15,611
-26,631
| -63% | -$1.07M | ﹤0.01% | 3346 |
|
|
2016
Q3 | $2.59M | Sell |
42,242
-14,645
| -26% | -$443K | ﹤0.01% | 2426 |
|
|
2016
Q2 | $1.09M | Sell |
56,887
-12,875
| -18% | -$238K | ﹤0.01% | 2844 |
|
|
2016
Q1 | $1.36M | Sell |
69,762
-6,667
| -9% | -$116K | ﹤0.01% | 2716 |
|
|
2015
Q4 | $2.95M | Sell |
76,429
-24,803
| -25% | -$804K | ﹤0.01% | 2393 |
|
|
2015
Q3 | $3.25M | Sell |
101,232
-5,395
| -5% | -$183K | ﹤0.01% | 2300 |
|
|
2015
Q2 | $3.25M | Buy |
106,627
+83,262
| +356% | +$1.7M | ﹤0.01% | 2430 |
|
|
2015
Q1 | $311K | Buy |
+23,365
| New | +$311K | ﹤0.01% | 3402 |
|
|
2014
Q4 | – | Sell |
-20,155
| Closed | -$425K | – | 4326 |
|
|
2014
Q3 | $425K | Buy |
20,155
+19,930
| +8,858% | +$450K | ﹤0.01% | 3095 |
|
|
2014
Q2 | $7K | Sell |
225
-295
| -57% | -$9.32K | ﹤0.01% | 4826 |
|
|
2014
Q1 | $12K | Buy |
520
+425
| +447% | +$10.8K | ﹤0.01% | 4458 |
|
|
2013
Q4 | $2K | Sell |
95
-48,168
| -100% | -$1.43M | ﹤0.01% | 4889 |
|
|
2013
Q3 | $2.28M | Sell |
48,263
-190,035
| -80% | -$7.32M | ﹤0.01% | 2380 |
|
|
2013
Q2 | $9.07M | Buy |
+238,298
| New | +$8.52M | 0.01% | 1492 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Ameriprise's SRPT Position: Q1 2026 in Review
Ameriprise increased its Sarepta Therapeutics (SRPT) stake by 20% in Q1 2026, buying an estimated $848K and bringing the position to 261,310 shares worth $5.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2350.
Ameriprise first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $272M in Q4 2020. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Ameriprise held 261,310 shares of Sarepta Therapeutics worth $5.69M as of Q1 2026.
- Ameriprise bought 43,799 Sarepta Therapeutics shares in Q1 2026, an estimated $848K.
- Sarepta Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2350 holding.
- Ameriprise first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Ameriprise's Sarepta Therapeutics position peaked at $272M in Q4 2020.
- 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.